The OS for integrative oncology — through treatment and the years after it
iksa is the harness for n‑of‑1 medicine. The oncologist gets a supportive plan built on one cited account of what the patient takes, and anything they want to add reaches your nurse first.
Surveillance belongs to the oncology team, and you follow what they find because the supportive plan has to fit whatever comes next
You leave the cancer to that team and still read every result they order, and the trial of one you run is the plan for how a patient sleeps, moves and feels, with those as its endpoints. What the patient takes and how they’re doing are yours, and the ctDNA, the CEA and the CT are the oncology team’s, set here for stage III colon cancer.
- Every three months for two years, because the patient’s oncologist orders itTumor-informed ctDNA: It’s strongly prognostic, yet NCCN’s colon guideline doesn’t recommend it for surveillance and sets no interval. Neither DYNAMIC-III, escalating chemotherapy on a detection after surgery, nor ALTAIR, starting a drug on one during follow-up, showed a significant recurrence benefit. It can miss recurrence, most of all in lung or peritoneum, so not detected never replaces the CT.
- Every three to six months for five yearsCEA: That interval is ASCO’s guideline, and the patient’s oncologist draws it every three months, the frequent end for stage III. Cochrane calls it too insensitive to use alone, and smoking, another illness or nothing anyone can find can raise it. So a rise goes straight to the oncologist, who usually confirms it on a repeat before deciding on imaging.
- Every six to twelve months for five yearsCT of the chest, abdomen and pelvis: That interval is NCCN’s guideline, ASCO’s is once a year for three years, and the oncologist chose six months. COLOFOL found no significant difference in five-year mortality between testing more and less often, so the interval is a judgment and it’s theirs.
- Before anything is added, and again whenever the patient’s treatment changesWhat the patient takes, beside their treatment: Some supplements change how the liver clears a drug, some thin the blood before a procedure, some act on a hormone a treatment depends on, and SWOG S0221 linked certain ones during chemotherapy with more recurrence in breast cancer. So the oncologist and a pharmacist see your list before anything starts.
- Each visit on one instrument, each cycle while treatment lastsFatigue, pain, sleep, mood and function: This is what moves your plan. Where the SIO-ASCO guidelines speak, they name therapies: for fatigue after treatment, exercise, CBT and mindfulness-based programs, with yoga, acupressure and moxibustion as options (ASCO-SIO 2024); acupuncture for aromatase-inhibitor joint pain, and acupuncture, reflexology or acupressure for general cancer pain (SIO-ASCO 2022); for anxiety and depression, mindfulness-based programs and yoga throughout, with relaxation, music therapy and reflexology during treatment and tai chi or qigong after it (SIO-ASCO 2023). Their recommendations cover symptoms and your note keeps to them, so nobody opening it mistakes it for treatment of the cancer.
The integrative doctor wrote the exercise plan, then asked the oncologist to sign it before the patient started
The patient’s plan is written for fatigue and function. Their oncologist knows the phase 3 trial in their cancer (New England Journal of Medicine, 2025): in 889 patients after surgery and adjuvant chemotherapy, a three-year structured exercise program improved disease-free survival over health-education materials (hazard ratio 0.72; 80.3% vs 73.9% at five years), with findings consistent with longer overall survival (hazard ratio for death 0.63) and more musculoskeletal adverse events (18.5% vs 11.5%). It’s evidence for that program alone and no promise to this patient.
What does your protocol say happens when a CEA rises, and who hears from you first?
Request a walkthroughRequest a walkthrough for integrative oncologyThe patient’s two teams keep two charts, where a cancer trial would keep one log of what they take
A coordinator keeps that log and asks at each visit, and a pharmacist checks it against the study drug. The oncology team’s people work on their own plan, so keeping the two charts in step comes down to you.
Concomitant medications
What you recommended is in your notes, what they prescribed is in theirs, and the capsules the patient’s sister sent may be in neither, because patients often don’t mention these to an oncologist unless someone asks.
Source documents
The patient has often been told before the CT, CEA and ctDNA reach you by portal, by fax or on their phone, so you may first hear a result from them.
Safety reporting
The new back pain, the weight the patient has lost or the cough that won’t go often comes to you first, because you’re the one with an hour to listen, and you get it to the team who can order a scan.
Patient-reported outcomes
Fatigue, sleep, pain and mood are your plan’s endpoints, and a trial would score them on one instrument at set times, where your plan reads them visit by visit.
When the doctor writes to the oncologist, the patient’s record already holds what they take and what changed, with the note behind each line
The harness follows the markers the patient’s supportive plan names, beside what your notes say about their fatigue, and each call about the cancer stays with the team who signed the plan off.
That letter starts from what the record says they take, and the integrative doctor can see where it says nothing
Clinical Intelligence lists it in the record’s words with each source cited, and a supplement the patient mentioned in passing that never reached a note or a summary of their messages comes back as a blank.
Clinical Intelligence: clinical AI and lab trackingThe nurse hears when the patient wants to add what their sister sent, so the doctor can raise it with the oncologist first
With the patient’s yes, that reaches your nurse as a flag. When a family asks whether your clinic could stand in for chemotherapy, Agentic CRM writes nothing, because a question about a patient’s cancer or their treatment goes straight to a person.
Agentic CRM: scheduling and follow-upThe patient asks Patient AI how hard their walks should feel and why the plan went to the oncologist first
Patient AI explains the plan from their record and what the doctor wrote, including that note’s word that what a scan or a ctDNA means is the oncologist’s to tell them. A new back pain or a cough that won’t go opens on safety questions and can reach the nurse or doctor.
Patient AI: the treatment companion
Exercise evidence for fatigue and function leans on breast and prostate cancer, and your records could start a study where it runs thin
An American College of Sports Medicine roundtable notes most of its trials are in early breast and prostate cancer, yet reasonably assumes the same benefit in other early-stage cancers without a unique safety concern. In colon cancer, CHALLENGE has since gone further, lengthening disease-free survival. The plans your patients’ oncologists signed and the symptoms written beside them could become a first study with a research group, with each patient’s consent, de-identified and after ethics review. It would ask how patients sleep, move and feel, and leave whether a supportive plan changes a cancer’s course to the trials built to ask that. What a first study in supportive care would take →
Where your plan stops and the oncology team’s begins
Does the oncology team stay in charge of treatment?
Entirely.The cancer and each decision about treating it stay with the oncology team. Your plan covers fatigue, sleep, mood, pain and how the patient moves, your note says so, and iksa flags, drafts and cites around that without touching what that team decides.
Does iksa read the ctDNA report or the CT?
Not for what they mean.A CT report goes on file as a document, dated and by kind, and iksa has no reader of its own for what a ctDNA means. It carries forward what your note and the oncologist’s letter say about them, with the source cited.
Will it flag a rising CEA?
Your nurse sees it.A CEA your note follows sits on your nurse’s list by status, and a value from the oncology team’s report reaches you only after it’s checked against its source page. A rise still inside the range raises no flag, so reading the run of values is yours, whether to repeat it or image is the oncologist’s call, and nothing goes on your plan aimed at that number.
Can it check a supplement against a patient’s chemotherapy?
No, you do.The supplement list your notes keep is on the patient’s record with the note behind it, and Clinical Intelligence can list it when the oncology team changes their treatment. Whether one of those can sit beside that treatment is a judgment for you and an oncology pharmacist, written in your note.
Does the oncology team have to use iksa?
Nothing changes for them.Their letters and reports reach you the way they do now, what someone files in your chart enters the patient’s record, and a letter that reads as a consultation note is there for Clinical Intelligence to cite, while the letter you send back stays yours to write and sign.
Can I keep Patient AI from someone mid-treatment?
One patient at a time.It reaches a patient only on that patient’s individual grant, and it can be paused for them whenever you ask. It doesn’t diagnose, so whether a result says anything about their cancer is answered as a doctor’s call and, on their yes, flagged to your nurse.
The integrative oncology software I’ve seen is built for infusion centers. Is this an OS for integrative oncology?
For the plan beside theirs.We call it the harness for n‑of‑1 medicine, because the plan you run for one patient only holds if it keeps answering to a cancer plan you didn’t write and can’t change.
What is n‑of‑1 medicine?All practicesiksa beside your EHRProtocol management softwareWhat iksa adds
Let’s read a supportive plan together, with what you check before adding anything and what the oncologist signs
Bring a protocol you run. We’ll walk one patient through it.